Endoscopic duodenal-jejunal bypass liner treatment for type 2 diabetes and obesity : glycemic and cardiovascular disease risk factor improvements in 1,022 patients treated worldwide

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00084124" target="_blank" >RIV/00023001:_____/23:00084124 - isvavai.cz</a>

Výsledek na webu

<a href="https://diabetesjournals.org/care/article/46/4/e89/148378/Endoscopic-Duodenal-Jejunal-Bypass-Liner-Treatment" target="_blank" >https://diabetesjournals.org/care/article/46/4/e89/148378/Endoscopic-Duodenal-Jejunal-Bypass-Liner-Treatment</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2337/dc22-1952" target="_blank" >10.2337/dc22-1952</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Endoscopic duodenal-jejunal bypass liner treatment for type 2 diabetes and obesity : glycemic and cardiovascular disease risk factor improvements in 1,022 patients treated worldwide

Popis výsledku v původním jazyce

There is a worldwide pandemic of type 2 diabetes (T2D) and obesity. In clinical practice, many patients with obesity have poor glycemic management despite diet and lifestyle advice and maximal medications. In this situation, Roux-en-Y gastric bypass is highly effective, and increased use of bariatric surgery has been recommended. Nevertheless, it is an invasive and irreversible surgical procedure. EndoBarrier (GI Dynamics, Boston, MA), also known as duodenal-jejunal bypass liner, is a 60-cm impermeable fluoropolymer sleeve that is implanted endoscopically into the upper part of the small intestine, left in place for up to 1 year, and then removed endoscopically. The duodenal-jejunal bypass liner was developed to mimic the proposed small-bowel mechanisms of Roux-en-Y gastric bypass (2–4) while being less invasive. In Europe in 2017, approval for use (certificate of Conformité Européenne, or CE mark) of EndoBarrier was not renewed for reasons that are not entirely clear. As over 3,000 patients have been treated with EndoBarrier worldwide, during 2017, an independent, secure, online registry was established by the Association of British Clinical Diabetologists (ABCD) for the collection of safety and efficacy data of EndoBarrier-treated patients worldwide.

Název v anglickém jazyce

Endoscopic duodenal-jejunal bypass liner treatment for type 2 diabetes and obesity : glycemic and cardiovascular disease risk factor improvements in 1,022 patients treated worldwide

Popis výsledku anglicky

There is a worldwide pandemic of type 2 diabetes (T2D) and obesity. In clinical practice, many patients with obesity have poor glycemic management despite diet and lifestyle advice and maximal medications. In this situation, Roux-en-Y gastric bypass is highly effective, and increased use of bariatric surgery has been recommended. Nevertheless, it is an invasive and irreversible surgical procedure. EndoBarrier (GI Dynamics, Boston, MA), also known as duodenal-jejunal bypass liner, is a 60-cm impermeable fluoropolymer sleeve that is implanted endoscopically into the upper part of the small intestine, left in place for up to 1 year, and then removed endoscopically. The duodenal-jejunal bypass liner was developed to mimic the proposed small-bowel mechanisms of Roux-en-Y gastric bypass (2–4) while being less invasive. In Europe in 2017, approval for use (certificate of Conformité Européenne, or CE mark) of EndoBarrier was not renewed for reasons that are not entirely clear. As over 3,000 patients have been treated with EndoBarrier worldwide, during 2017, an independent, secure, online registry was established by the Association of British Clinical Diabetologists (ABCD) for the collection of safety and efficacy data of EndoBarrier-treated patients worldwide.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Diabetes care

ISSN

0149-5992

e-ISSN

1935-5548

Svazek periodika

46

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

3

Strana od-do

"e89"-"e91"

Kód UT WoS článku

001046687500001

EID výsledku v databázi Scopus

2-s2.0-85151043009